Dr Reddy's Laboratories Profit Margin 2006-2019 | RDY

Current and historical gross margin, operating margin and net profit margin for Dr Reddy's Laboratories (RDY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Dr Reddy's Laboratories net profit margin as of September 30, 2019 is 16.2%.
Dr Reddy's Laboratories Annual Profit Margins
Dr Reddy's Laboratories Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $7.035B $2.225B
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.252B 11.53
Mylan (MYL) United States $11.179B 5.01
Teva Pharmaceutical Industries (TEVA) Israel $11.139B 4.53
Bausch Health Cos (BHC) Canada $10.661B 7.03
ASPEN PHARMACR (APNHY) South Africa $3.743B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.282B 12.41
Amphastar Pharmaceuticals (AMPH) United States $0.943B 48.98
Homology Medicines (FIXX) United States $0.764B 0.00
Voyager Therapeutics (VYGR) United States $0.511B 0.00
Assembly Biosciences (ASMB) United States $0.459B 0.00
Mallinckrodt Public (MNK) United Kingdom $0.437B 0.60
Progenics Pharmaceuticals (PGNX) United States $0.405B 0.00
Sol-Gel Technologies (SLGL) Israel $0.265B 0.00
Akorn (AKRX) United States $0.170B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.164B 0.00
CymaBay Therapeutics (CBAY) United States $0.139B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.132B 0.00
Teligent (TLGT) United States $0.022B 0.00